[Recent progress in hematopoietic stem cell transplantation]

Area of Science:

• Hematology
• Immunology
• Oncology

Context:

• Allogeneic stem cell transplantation (allo-SCT) indications have broadened with diverse stem cell sources and reduced intensity conditioning (RIST).
• Available stem cell sources include bone marrow, peripheral blood, and cord blood from related or unrelated donors.
• HLA-mismatched and haploidentical donor transplantation are areas of active research.

Purpose:

• To review the expanded indications and evolving landscape of allogeneic stem cell transplantation.
• To highlight the benefits of reduced intensity stem cell transplantation (RIST) in broadening allo-SCT applicability.
• To identify unresolved challenges in allo-SCT, including graft-versus-leukemia (GVL) and graft-versus-host disease (GVHD) management.

Summary:

• The expansion of allo-SCT is driven by the availability of various stem cell sources and the development of RIST, which reduces regimen-related toxicity.
• RIST has made allo-SCT feasible for a wider patient population.
• Key challenges persist in optimizing the graft-versus-leukemia (GVL) effect and controlling graft-versus-host disease (GVHD).

Impact:

• Improved selection of compatible stem cell sources is crucial for recipient condition and disease status.
• Further research into chronic GVHD therapy and post-transplant complications is necessary.
• Enhanced management strategies are needed to improve patient outcomes and quality of life after allo-SCT.